Eczema is one of the most common reasons a patient searches for an online skin consultation, and most cases genuinely fit a remote model: a flare, a pattern the patient has seen before, a request for the same strength cream that worked last time. The operational challenge is drawing a line that holds under scrutiny between that routine case and the minority that needs hands-on assessment or specialist dermatology, and building the service so the line gets checked on every consultation, not just the first one.
What counts as eczema in a telehealth remit
Atopic eczema is a chronic, relapsing, itchy skin condition, usually diagnosed on history and visual pattern rather than any test, which is part of why it translates to remote consultation better than conditions that need biopsy or bloods. A typical presentation, itch plus a visible flexural or facial rash with a history of previous flares, is assessable from a structured history and clear photographs.
The remit narrows quickly outside that typical picture. Atypical distribution, a rash that doesn't fit the patient's usual pattern, or a first-ever presentation in an adult all raise the bar for diagnostic confidence, and a service that can't examine skin texture or check for secondary signs in person should treat uncertainty as a reason to slow down, not a reason to guess and prescribe anyway.
Diagnosis and triage without hands-on examination
History carries most of the diagnostic weight: age of onset, family or personal history of atopy, distribution, triggers, and what's been tried already. Photos fill the gap a text description leaves, provided the service asks for images at a resolution and angle that actually show the skin, not a blurry proxy for one.
Some presentations need same-day escalation rather than a routine photo review. Build these into the triage flow as hard stops, not clinician discretion alone:
- Clustered blisters, punched-out erosions, or crusting with fever or malaise, which can indicate eczema herpeticum and needs urgent face-to-face assessment, not a remote steroid script
- Widespread weeping, swelling or signs suggestive of bacterial superinfection
- A rash that doesn't fit any typical eczema pattern, raising the possibility of psoriasis, scabies, contact dermatitis or fungal infection instead
- Eye involvement near the eczema site, which carries its own referral threshold
- Rapid deterioration despite treatment the patient was already using correctly
The stepped treatment ladder: emollients to topical steroids
Emollients are the foundation, used liberally and continued even during a flare, and a service that skips straight to a steroid prescription without reinforcing emollient use is treating the symptom while leaving the maintenance work undone. From there, treatment follows a stepped ladder: mild-potency topical corticosteroid for mild disease, moderate or potent for more significant flares, matched to the site and the patient's age.
Topical calcineurin inhibitors, tacrolimus or pimecrolimus, have a defined role as steroid-sparing options for sensitive sites such as the face and skin folds, or where repeated steroid courses are becoming a concern. A remote service should be explicit in its own clinical protocol about which step a given presentation and history justify, rather than defaulting every flare to the same strength cream a patient asks for by name.
Eczema fits a remote model for the typical case, but the service only stays safe if eczema herpeticum, treatment failure, and repeated potent-steroid courses trigger a hard stop, not a clinician's discretion on a busy day.
Steroid stewardship and the questions patients ask
Steroid phobia is common and works in both directions: some patients under-treat out of fear of thinning skin, others over-request a stronger cream than the presentation needs because a previous one worked quickly. A good consultation addresses both, explaining fingertip-unit dosing, expected course length, and why potent steroids need tighter time limits on the face and in flexures than on thicker skin elsewhere on the body.
Prolonged or repeated potent-steroid use without review is the pattern that causes real harm, skin thinning, striae, and in rare cases systemic absorption, so the service's protocol should cap how many consecutive courses a patient can get without a structured review rather than an unlimited repeat-request pathway.
Paediatric eczema: a tighter remit
Eczema is especially common in children, and a telehealth service that serves families needs a more conservative default: lower steroid potencies as the starting point, caution with calcineurin inhibitors below two years of age, and a lower threshold for asking to see the child rather than relying on a parent's description alone. See our paediatric medicines cautions guide for how this reshapes dosing and consent across remote prescribing generally.
Consent sits with the parent or carer for younger children, but a service seeing teenagers managing their own skin condition should have a clear position on Gillick competence and when the young person, not just the parent, is the patient making the decision. Our Gillick competence guide covers the practical test for that.
A photo review that can't tell a routine flare from eczema herpeticum isn't triage, it's a guess with a prescription attached.
The referral line: when it's dermatology's case, not yours
The clearest signal that a case has outgrown a telehealth remit is treatment failure: eczema that hasn't responded to an adequately potent topical steroid used correctly, or that needs stepping beyond topical therapy altogether. That's the point to refer into dermatology for phototherapy, systemic immunosuppressants, or a biologic such as dupilumab, rather than cycling the patient through another round of the same cream at the same strength.
This is the same discipline we set out in our psoriasis telehealth guide and our isotretinoin guide: a dermatology sub-vertical only works remotely for as long as the operator treats the referral line as the real clinical safeguard, reviewed on every consultation, not a form filled in once at onboarding.
Where PExpo fits
PExpo provides the regulated layer behind a telehealth brand: registered dispensing, prescriber governance, pharmacovigilance and the patient record, so an eczema service can launch with the triage red flags, the steroid stewardship rules and the referral thresholds built into the clinical protocol from day one rather than retrofitted after a near-miss. See our dermatology telehealth guide for how eczema sits alongside psoriasis, acne and rosacea as sub-niches within the same broader vertical.
You bring the brand and the funnel; the clinical judgement on where topical treatment ends and specialist referral begins sits with an operator that runs this pathway routinely. See our clinic model and pricing.
Eczema is a good fit for telehealth precisely because most cases are familiar and low-risk, but that only holds if the protocol treats the exceptions as hard stops rather than edge cases to handle on instinct. Pair the stepped treatment ladder with the referral line and the paediatric caveats, and the service covers the vertical safely. See our launch checklist and clinical SOPs guide for the operational detail that sits underneath this.
Frequently asked questions
Can eczema be diagnosed remotely?
Typical atopic eczema, an itchy flexural or facial rash with a history of previous flares, can usually be assessed from a structured history and clear photographs. A first-ever presentation in an adult, an atypical distribution, or any sign of infection should raise the bar for diagnostic confidence and may need in-person assessment instead.
What are the red flags for eczema herpeticum?
Clustered blisters, punched-out erosions or widespread crusting, especially alongside fever or malaise, are the signs that point to eczema herpeticum. This needs urgent face-to-face assessment rather than a remote steroid prescription, so a telehealth protocol should treat it as a hard stop in triage, not a judgement call.
When should an eczema case be referred to dermatology instead of treated online?
Referral is appropriate once eczema fails to respond to an adequately potent topical steroid used correctly, or once the case needs treatment beyond topicals, such as phototherapy, systemic immunosuppressants or a biologic. Repeated potent-steroid courses without improvement are a signal to refer rather than repeat the same prescription.
